NCT07610005招募中1 期
A Phase 1, Open-Label, Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Varegacestat Administered in Different Dose Forms in Healthy Participants
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, adult, female of non childbearing potential or male, 18 to 55 years of age, inclusive, at the screening visit
- •Male participants must follow protocol-specified contraception guidance
- •Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing
- •BMI ≥ 18.0 and ≤ 32.0 kg/m2 and with a body weight > 50 kg at the screening visit
- •Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee
- •Able to swallow multiple capsules
排除标准
- •Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
- •History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee
- •History of any illness that, in the opinion of the PI or designee might confound the results of the study or poses an additional risk to the participant by their participation in the study
- •History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
- •History or presence of hypersensitivity or idiosyncratic reaction to varegacestat or related compounds
- •History or presence of:
- •Autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus
- •Thrombophlebitis or deep vein thrombosis
- •Hematologic or coagulation disorders
- •Liver disease or dysfunction; Gilbert's syndrome
- •Renal dysfunction or glomerulonephritis
- •Cancer (except treated basal cell carcinoma of the skin and cancer-free for 5 years, non metastatic basal or squamous cell carcinoma of the skin, and cervical carcinoma in situ)
- •Clinically significant cardiovascular, gastrointestinal, pulmonary, endocrine, central nervous system disorders, or other major active and uncontrolled disease in the opinion of the PI or designee.
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Oral bioavailability study of test product to evaluate the safety, tolerability, and Pharmacokinetics in healthy human subjects.CTRI/2025/12/099939LipoSeuticals Inc16
招募中
1 期
A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy SubjectsCardiomyopathyNCT07272330Shandong Suncadia Medicine Co., Ltd.38
已完成
1 期
Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.Healthy volunteers2026-525930-47-00Farmalider S.A.8
已完成
不适用
An Open Label Single Dose Two Treatment Two Period Oral Bioavailability Study Comparing Apixaban 5 mg Oral Solution with Eliquis Apixaban 5 mg Film Coated Tablets In Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2025/08/092901Mahashiv Limited32
进行中（未招募）
不适用
Single Dose Two Treatment Four Period Oral Bioavailability Study Comparing Esomeprazole 20 mg Capsule In Healthy Adult Human Subjects Under Fed ConditionsCTRI/2025/09/095396Nova Pharmaceuticals Australasia Pty Ltd48